Elucidating the Relationship Between Diabetes Mellitus and Parkinson’s Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2-Reference-Cited by-同舟云学术

Elucidating the Relationship Between Diabetes Mellitus and Parkinson’s Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2

Published:2020-07-14 Issue: Volume:14 Page:
ISSN:1662-453X
Container-title:Frontiers in Neuroscience
language:
Short-container-title:Front. Neurosci.

Author:

Kong Yanyan,Zhou Haicong,Feng Hu,Zhuang Junyi,Wen Tieqiao,Zhang Chencheng,Sun Bomin,Wang Jiao,Guan Yihui

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

General Neuroscience

Reference111 articles.

1. Cognitive dysfunction in drug-induced parkinsonism caused by prokinetics and antiemetics.;Ahn;J. Korean Med. Sci.,2015

2. Cytokines and acute neurodegeneration.;Allan;Nat. Rev. Neurosci.,2001

3. Val66Met BDNF polymorphism is associated with Parkinson’s disease cognitive impairment.;Altmann;Neurosci. Lett.,2016

4. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.;Anlauf;J. Histochem. Cytochem.,2003

5. Diagnosis and treatment of parkinson disease: a review.;Armstrong;JAMA,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of hyperbaric oxygen therapy in diabetic foot ulcers: A meta‐analysis;International Wound Journal;2024-03-26

2. First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133);2024-02-28

3. The Regulation of Neuro-immune System by Pi (Parasympathetic) and SiGMA (Sympathetic Induction Governed by Meditation and Asana) Rhythmicity;Neuroscience of Yoga;2024

4. Recent progress in the applications of presynaptic dopaminergic positron emission tomography imaging in parkinsonism;Neural Regeneration Research;2023-12-21

5. Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?;Frontiers in Molecular Neuroscience;2023-05-25